Piramal Pharma's 200-Plus Audits Signal Quality Edge

Piramal Pharma Solutions, the CDMO arm of Piramal Pharma Ltd. (NSE: PPLPHARMA), said it completed more than 200 customer audits and received over 70 regulatory approvals across its global network in the past fiscal year. The company framed the results as evidence that its long-range quality strategy is working.

The strategy combines governance and quality culture with digital transformation. A program called RESOLVE targets right-first-time execution in manufacturing and QC labs. The company also uses predictive quality tools to assess site readiness and compliance health.

On the digital side, PPS has deployed eLab to digitize QC labs and automate testing. A separate tool, exForms, digitizes GxP forms to improve accessibility and accelerate approvals. A third platform, iAssist, uses AI to structure investigation outputs. The company said these tools reduce errors and support continuous audit readiness.

"Quality is integral to everything we do," said Chief Quality Officer Rashida Najmi. "Our focus is on building quality into everyday operations so that audit readiness is sustained, not episodic."

A strong audit record is table stakes for a CDMO. It helps retain existing clients and win new contracts. The cost of these digital investments and training programs will show up in operating margins. Whether the quality push translates into revenue growth or just higher costs is an open question. The next earnings report will offer the first look at that trade-off.